Cardiff Oncology Inc CRDF
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Cardiff Oncology to Participate in the UBS Global Biopharma Conference
-
Cardiff Oncology Appoints Leila Alland, MD, as Interim Chief Medical Officer
-
Cardiff Oncology Receives FDA Orphan Drug Designation for Onvansertib in Chronic Myelomonocytic Leukemia
-
Cardiff Oncology and Nerviano Medical Sciences Amend their 2017 Exclusive License Agreement
-
Cardiff Oncology to Participate in September 2026 Conferences
-
Cardiff Oncology Reports Second Quarter 2026 Results and Provides Business Update
-
These 16 stocks are a short seller's dream - likely losers no matter what the market does
Trading Information
- Previous Close Price
- —
- Day Range
- —–—
- 52-Week Range
- —–—
- Bid/Ask
- — / —
- Shares Outstanding
- 77.80M
- Market Cap
- —
- Volume/Avg
- — / —
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 115.14
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Cardiff Oncology Inc is a clinical-stage biotechnology company advancing cancer treatments focused on PLK1 inhibition, a validated oncology target with practice-changing potential. Its main asset, onvansertib, is a specific, oral PLK1 inhibitor currently being evaluated in a Phase 2 trial for first-line treatment of RAS-mutated metastatic colorectal cancer (mCRC), addressing a large, underserved patient population with high unmet need. Onvansertib is also under investigation in other PLK1-driven cancers through ongoing investigator-initiated trials and has shown robust single agent clinical activity in hard-to-treat tumors. By targeting tumor vulnerabilities, to overcome treatment resistance and deliver improved clinical outcomes for patients.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 31
- Website
- https://www.cardiffoncology.com
Valuation
|
Metric
|
CRDF
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 2.23 |
Price/Sales | 115.14 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
CRDF
|
|---|---|
Quick Ratio | 3.21 |
Current Ratio | 3.30 |
Interest Coverage | — |
Quick Ratio
CRDF
Profitability
|
Metric
|
CRDF
|
|---|---|
Return on Assets (Normalized) | −60.48% |
Return on Equity (Normalized) | −81.36% |
Return on Invested Capital (Normalized) | −84.90% |
Return on Assets
CRDF
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|@#$@h< | LOCK|%#qh% | $135B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|S!@l?nn | LOCK|#X$by | $101B | |||
| Moderna Inc
MRNA
| LOCK|#Wl@Q?# | LOCK|@N | $91B | |||
| argenx SE ADR
ARGX
| LOCK|<^pX@! | LOCK|%@x | $56B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|@kN>#>X | LOCK|&Nb | $41B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|^@SV@%M | LOCK|pw^N | $30B | |||
| Incyte Corp
INCY
| LOCK|@KVb>@C | LOCK|g# | $24B | |||
| BioNTech SE ADR
BNTX
| LOCK|sT?LqD | LOCK|$l | $22B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|<qgb%z | LOCK|Zr&z | $21B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|Y?$%VlF | LOCK|>x | $15B |
United States